Macrogenics
MGNX
Macrogenics (MGNX) news
Recent news
MacroGenics 2Q revenue $32.8M, estimate $31.8M
MacroGenics (NASDAQ: MGNX) reported second-quarter 2026 revenue of $32.8 million, exceeding the estimated $31.8 million . This marks a significant improvement compared to the same period in 2025, when the company reported a revenue of $22.2 million, representing a year-over-year increase of…
AInvest Wire · Aug 13, 2026MacroGenics says Gilead exercises option, triggers $10M payment
AInvest Wire · Aug 11, 2026MacroGenics - remains eligible to receive up to approximately $1.6 bln in additional development
AInvest Wire · Aug 11, 2026Gilead Sciences exercises option for exclusive license for a preclinical bispecific program, triggers $10 mln payment to Macrogenics
AInvest Wire · Aug 11, 2026MacroGenics: achieved pre-specified Stage 1 response threshold
AInvest Wire · Jul 23, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.